Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment-Reference-Cited by-同舟云学术

Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment

Published:2018-06 Issue: Volume:423 Page:9-15
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Li Weihua,Qiu Tian,Guo Lei,Ling Yun,Gao Yibo,Ying Jianming,He Jie

Funder

National Natural Science Foundation of China

CAMS

State Key R&D Program

Beijing Hope Run Special Fund of Cancer Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. New and emerging targeted treatments in advanced non-small-cell lung cancer;Hirsch;Lancet,2016

2. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials;Gao;Int. J. Canc.,2012

3. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts;Li;Br. J. Canc.,2014

4. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis;Kuan;Br. J. Canc.,2015

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment;Lung Cancer;2024-04

2. Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses;Clinical and Translational Oncology;2024-01-08

3. The landscape of actionable genomic alterations in lung adenocarcinomas in India;Frontiers in Genetics;2023-12-13

4. Long-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in India;International Journal of Molecular and Immuno Oncology;2023-11-25

5. The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality;Journal of Thoracic Oncology;2023-09